AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
XTL Biopharmaceuticals Ltd. American Depositary Shares
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SKMNX1
2.02▲ 0.05 (2.54%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
1.97
Day's Range
1.97 – 2.02
52-Week Range
0.53 – 4.87
Volume
3,682
Avg Volume
7,181
Share Statistics
Shares Outstanding
Employees
2
Exchange
XNAS
Listed
2005-09-01
Share count as of December 31, 2025

XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about XTL Biopharmaceuticals Ltd. American Depositary Shares (XTLB)
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's Market Cap?
XTL Biopharmaceuticals Ltd. American Depositary Shares's Market Cap is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's Enterprise Value?
XTL Biopharmaceuticals Ltd. American Depositary Shares's Enterprise Value is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's EV / EBITDA?
XTL Biopharmaceuticals Ltd. American Depositary Shares's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's Revenue (TTM)?
XTL Biopharmaceuticals Ltd. American Depositary Shares's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's Net Income (TTM)?
XTL Biopharmaceuticals Ltd. American Depositary Shares's Net Income (TTM) is -$7.0M, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's EBITDA?
XTL Biopharmaceuticals Ltd. American Depositary Shares's EBITDA is -$1.7M, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's Diluted EPS (TTM)?
XTL Biopharmaceuticals Ltd. American Depositary Shares's Diluted EPS (TTM) is -0.01, based on as-reported figures from SEC (XBRL) filings.
What is XTL Biopharmaceuticals Ltd. American Depositary Shares's Net Debt?
XTL Biopharmaceuticals Ltd. American Depositary Shares's Net Debt is -$76.0K, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · XTLBAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Research and development expenses
General and administrative expenses
Other expenses
Operating loss
Change in fair value of financial instruments
Change in fair value of marketable securities
Change in fair value of convertible loan from shareholder
Interest expenses
Other finance income
Other finance expenses
Finance income (expenses), net
Loss before income taxes
Profit (loss) from continuing operations
Loss from discontinued operations, net of tax
Net loss for the year